NASDAQ:IONS - Ionis Pharmaceuticals Stock Price, News & Analysis

$66.20
-0.68 (-1.02 %)
(As of 09/15/2019 10:57 AM ET)
Today's Range
$62.3550
Now: $66.20
$64.36
50-Day Range
$60.25
MA: $65.63
$72.40
52-Week Range
$43.27
Now: $66.20
$86.58
Volume417,751 shs
Average Volume938,711 shs
Market Capitalization$9.30 billion
P/E Ratio20.27
Dividend YieldN/A
Beta1.97
Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:IONS
CUSIP46433010
Phone760-931-9200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$599.67 million
Cash Flow$3.1675 per share
Book Value$8.63 per share

Profitability

Net Income$273.74 million

Miscellaneous

Employees737
Market Cap$9.30 billion
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable

Receive IONS News and Ratings via Email

Sign-up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.


Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions

What is Ionis Pharmaceuticals' stock symbol?

Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."

How were Ionis Pharmaceuticals' earnings last quarter?

Ionis Pharmaceuticals Inc (NASDAQ:IONS) issued its quarterly earnings results on Wednesday, August, 7th. The company reported ($0.01) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.27) by $0.26. The firm earned $164 million during the quarter, compared to the consensus estimate of $145.31 million. Ionis Pharmaceuticals had a return on equity of 38.70% and a net margin of 49.90%. The company's revenue for the quarter was up 39.0% on a year-over-year basis. During the same period last year, the company earned ($0.29) earnings per share. View Ionis Pharmaceuticals' Earnings History.

When is Ionis Pharmaceuticals' next earnings date?

Ionis Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Ionis Pharmaceuticals.

What price target have analysts set for IONS?

9 equities research analysts have issued twelve-month price objectives for Ionis Pharmaceuticals' stock. Their predictions range from $48.00 to $95.00. On average, they anticipate Ionis Pharmaceuticals' share price to reach $68.6667 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View Analyst Price Targets for Ionis Pharmaceuticals.

What is the consensus analysts' recommendation for Ionis Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 7 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.

What are Wall Street analysts saying about Ionis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (7/31/2019)
  • 2. Cantor Fitzgerald analysts commented, ". $68 PT. Biogen (BIIB, Young, Neutral) reported earnings this morning and discussed the outlook for Spinraza, which is a key product for Ionis (receives low-20s royalty). Incremental color suggests that the broader SMA market, especially ex-US, is likely much larger than initially expected. However, we see disruptive potential from competitors (risdiplam and gene therapy) which continues to leave us cautious on the long-term Spinraza opportunity. We are hosting a conference call on Monday at 10 AM ET to discuss our thoughts on the key SMA competitor updates expected at AAN (early May) and stock reads to IONS, BIIB and PTCT (Overweight, Young). Call details below." (4/24/2019)

Has Ionis Pharmaceuticals been receiving favorable news coverage?

Press coverage about IONS stock has trended somewhat positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a news impact score of 0.9 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Ionis Pharmaceuticals.

Who are some of Ionis Pharmaceuticals' key competitors?

What other stocks do shareholders of Ionis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), BlackRock (BLK), Alnylam Pharmaceuticals (ALNY), Gilead Sciences (GILD), Biogen (BIIB), Micron Technology (MU), Alibaba Group (BABA), Intercept Pharmaceuticals (ICPT), Endologix (ELGX) and Allergan (AGN).

Who are Ionis Pharmaceuticals' key executives?

Ionis Pharmaceuticals' management team includes the folowing people:
  • Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
  • Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
  • Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
  • Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
  • Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)

Who are Ionis Pharmaceuticals' major shareholders?

Ionis Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.15%), BlackRock Inc. (6.27%), BlackRock Inc. (6.27%), Baillie Gifford & Co. (6.02%), Waddell & Reed Financial Inc. (2.26%) and Invesco Ltd. (1.62%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.

Which major investors are selling Ionis Pharmaceuticals stock?

IONS stock was sold by a variety of institutional investors in the last quarter, including First Trust Advisors LP, Price T Rowe Associates Inc. MD, First Light Asset Management LLC, Scout Investments Inc., Baillie Gifford & Co., Waddell & Reed Financial Inc., Carillon Tower Advisers Inc. and Sector Gamma AS. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.

Which major investors are buying Ionis Pharmaceuticals stock?

IONS stock was acquired by a variety of institutional investors in the last quarter, including Invesco Ltd., Renaissance Technologies LLC, BlackRock Inc., BlackRock Inc., Sumitomo Mitsui Trust Holdings Inc., Nuveen Asset Management LLC, Vanguard Group Inc. and Janus Henderson Group PLC. View Insider Buying and Selling for Ionis Pharmaceuticals.

How do I buy shares of Ionis Pharmaceuticals?

Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Ionis Pharmaceuticals' stock price today?

One share of IONS stock can currently be purchased for approximately $66.20.

How big of a company is Ionis Pharmaceuticals?

Ionis Pharmaceuticals has a market capitalization of $9.30 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.View Additional Information About Ionis Pharmaceuticals.

What is Ionis Pharmaceuticals' official website?

The official website for Ionis Pharmaceuticals is http://www.ionispharma.com/.

How can I contact Ionis Pharmaceuticals?

Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.


MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  547 (Vote Outperform)
Underperform Votes:  604 (Vote Underperform)
Total Votes:  1,151
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 9/15/2019 by MarketBeat.com Staff

Featured Article: Earnings Reports

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel